PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis - 2016 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vtr9jv/pd1_and_pdl1) has announced the addition of the "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis - 2016" report to their offering.

PD-1 and PD-L1 Inhibitors-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the PD-1 and PD-L1 Inhibitors. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for PD-1 and PD-L1 Inhibitors. The report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Scope:

• The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors.
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

1. PD-1 and PD-L1 Inhibitors Overview
2. PD-1 and PD-L1 Inhibitors Pipeline Therapeutics
3. PD-1 and PD-L1 Inhibitors Therapeutics under Development by Companies
4. PD-1 and PD-L1 Inhibitors Filed and Phase III Products
5. Comparative Analysis
6. PD-1 and PD-L1 Inhibitors Phase II Products
7. Comparative Analysis
8. PD-1 and PD-L1 Inhibitors Phase I and IND Filed Products
9. Comparative Analysis
10. PD-1 and PD-L1 Inhibitors Discovery and Pre-Clinical Stage Products
11. Comparative Analysis
12. Drug Candidate Profiles
13. PD-1 and PD-L1 Inhibitors - Therapeutics Assessment
14. Assessment by Monotherapy Products
15. Assessment by Combination Products
16. Assessment by Route of Administration
17. Assessment by Molecule Type
18. PD-1 and PD-L1 Inhibitors - Discontinued Products
19. PD-1 and PD-L1 Inhibitors - Dormant Products
20. Companies Involved in Therapeutics Development for PD-1 and PD-L1 Inhibitors
    

For more information visit http://www.researchandmarkets.com/research/vtr9jv/pd1_and_pdl1